Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Official Title

An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Summary:

The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumour activity of CEP-18770 in patients treated at the MTD.

Trial Description

Primary Outcome:

• Overall Response Rate (ORR)

• Elapsed time from the ORR date to the date of disease progression (DOR)
• Elapsed time from the date of first dose of CEP-18770 to the date of first response (TTR) to treatment with CEP-18770
• Elapsed time from the date of first dose of CEP-18770 to the date of disease progression (TTP)

View this trial on ClinicalTrials.gov